雅仕维(01993.HK)飙43%曾见9.7元上市新高 引资蚂蚁金服兼研分拆业务
雅仕维(01993.HK)引资蚂蚁金服兼研分拆业务,该股今天逆市飙升曾突破2015年4月所创上市高位7.9元,最多飙升逾1倍至9.7元,现造6.7元,急涨42.6%,街货少及一向稀疏成交急增至53万股,为一年来最多,涉资379万元。
雅仕维公布,以每股4.1元(较昨天收市价折让约12.8%),向独立第三方蚂蚁金服配售3,567.56万股新股或占扩大後股本7.5%,所得净额1.43亿元,拟用作旗下中国和新加坡项目及一般营运资金。同时,公司现正考虑可能将在东南亚、香港和澳门的业务分拆及於一间认可证券交易所独立上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.